ANJI PHARMACEUTICALS

Anji is an asset-centric company built to rapidly pursue well-validated drug targets and improve the lives of patients everywhere. We recently completed a multinational Phase 2 proof-of-concept study for ANJ908 in chronic idiopathic constipation. Our Phase 3 program to bring ANJ900 to patients with type 2 diabetes and advanced chronic kidney disease is on track to deliver results in 2024... At Anji, "getting it done" is our north star. We prioritize high-value, late-stage therapies with human validation that they will work. It's an approach that brings higher clinical success rates, lower development costs, and long-term value for our partners. No red tape, no hype; just a steadfast focus on results that outperforms traditional asset-centric business models... We created Anji to improve the performance of asset-centric biopharmaceutical companies.

Also known as: Anji, Anji Pharma, ANJI PHARMACEUTICALS INC

Primary location: Cambridge United States